Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study compared treatment outcomes in patients with major depressive disorder treated with either duloxetine with a daily dose of ≤60 mg or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic setting in East Asia. In addition, this study examined the impact of painful physical symptoms (PPS) on the effects of these treatments.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Asia Pac Psychiatry

Title: Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists

Publisher: Wiley-Blackwell

ISSN (Electronic): 1758-5872

ISSN (Print): 1758-5864

Publication date (Electronic): Mar 2016

Volume: 8

Issue: 1

Affiliations

[1 ] Global Patient Outcomes and Real World Evidence (GPORWE), Eli Lilly and Company, Windlesham, Surrey, UK.

[2 ] Global Patient Outcomes and Real World Evidence (GPORWE), Eli Lilly Australia Pty Ltd, Sydney, NSW, Australia.

[3 ] Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain.

[4 ] EMBU Medical, Eli Lilly de Mexico, Mexico City, US.

[5 ] Global Patient Outcomes and Real World Evidence (GPORWE), Eli Lilly and Company, Indianapolis, IN, US.

Article

DOI: 10.1111/appy.12178

PubMed ID: 25808275

SO-VID: 4b75e218-299b-451e-852e-a46f8af67c91

History

Keywords: pain,Asia,SSRI,depression,duloxetine

Data availability:

Keywords: pain, Asia, SSRI, depression, duloxetine

Comments

Comment on this article

scite_

Cited by 7

See all cited by